{"id":"isoniazid-oral-product","safety":{"commonSideEffects":[{"rate":"1-2%","effect":"Peripheral neuropathy"},{"rate":"0.5-3%","effect":"Hepatotoxicity"},{"rate":"0.1-0.5%","effect":"Hypersensitivity reactions"},{"rate":"0.1-0.2%","effect":"Drug-induced lupus"},{"rate":"1-2%","effect":"Nausea and vomiting"},{"rate":"1-2%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid is a prodrug that requires activation by the mycobacterial enzyme catalase-peroxidase (KatG) to form an isonicotinoyl radical. This activated form binds to mycobacterial enoyl-ACP reductase (InhA), inhibiting the synthesis of mycolic acids that are critical structural components of the mycobacterial cell wall. This disruption of cell wall integrity leads to bacterial death and is bactericidal against actively dividing M. tuberculosis.","oneSentence":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:19.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB) - active disease treatment"},{"name":"Tuberculosis latent infection prevention"}]},"trialDetails":[{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT05175794","phase":"","title":"Triage Test for All Oral DR-TB Regimen (TRiAD Study)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-05-26","conditions":"Drug Resistant Tuberculosis, MDR-TB, XDR-TB","enrollment":786},{"nctId":"NCT05221502","phase":"PHASE2","title":"Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-04-12","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT06748937","phase":"PHASE2","title":"A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide","status":"RECRUITING","sponsor":"TASK Applied Science","startDate":"2025-03-03","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT06811792","phase":"","title":"Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2010-01-01","conditions":"Tuberculous Meningitis","enrollment":837},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04272242","phase":"PHASE2","title":"Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-27","conditions":"HIV Infection, LTBI","enrollment":37},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT06565845","phase":"","title":"Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2024-08-19","conditions":"Granulomatous Mastitis","enrollment":350},{"nctId":"NCT03510468","phase":"PHASE1","title":"Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2018-06-12","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT05330884","phase":"PHASE3","title":"BCG Revaccination in Children and Adolescents","status":"SUSPENDED","sponsor":"Tuberculosis Research Centre, India","startDate":"2024-07-15","conditions":"Tuberculosis Infection, Tuberculosis","enrollment":9200},{"nctId":"NCT05401071","phase":"PHASE2, PHASE3","title":"Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-13","conditions":"Tuberculosis, Pulmonary","enrollment":2442},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT03882177","phase":"PHASE2","title":"StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":"Tuberculosis, Pulmonary Tuberculosis","enrollment":16},{"nctId":"NCT05664568","phase":"PHASE2","title":"The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","status":"UNKNOWN","sponsor":"Western Sydney Local Health District","startDate":"2023-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT01936831","phase":"PHASE2","title":"High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-08-13","conditions":"Tuberculosis","enrollment":282},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT05215990","phase":"PHASE1, PHASE2","title":"Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-01-15","conditions":"Tuberculosis, Pulmonary","enrollment":80},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02236078","phase":"PHASE1","title":"Brief Bactericidal Activity of Anti-Tuberculosis Drugs","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-11","conditions":"Tuberculosis, Drug-resistant Tuberculosis, Isoniazid Resistant Tuberculosis (Disorder)","enrollment":18},{"nctId":"NCT02684240","phase":"PHASE2","title":"A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2016-02","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT00816426","phase":"PHASE1","title":"Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-29","conditions":"Tuberculosis","enrollment":19},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT00330304","phase":"PHASE3","title":"Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2003-01","conditions":"Tuberculosis","enrollment":450},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT00080119","phase":"PHASE2, PHASE3","title":"Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2004-02","conditions":"HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia","enrollment":1354},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT01516203","phase":"PHASE2","title":"Phase 2a EBA Trial of AZD5847","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-12-05","conditions":"Tuberculosis","enrollment":75},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT01399788","phase":"PHASE1","title":"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT02901288","phase":"PHASE4","title":"Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2016-08","conditions":"Tuberculosis, Pulmonary","enrollment":3900},{"nctId":"NCT02121314","phase":"PHASE2","title":"HRZE Fasted/Fed in Newly Diagnosed TB","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2013-07","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT02014272","phase":"PHASE1","title":"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT01785927","phase":"PHASE1","title":"The Safety of Tuberculosis Treatments by Oral Inhalation","status":"UNKNOWN","sponsor":"Prince of Songkla University","startDate":"2013-02","conditions":"Healthy","enrollment":40},{"nctId":"NCT00633256","phase":"NA","title":"The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-12","conditions":"Smoking","enrollment":20},{"nctId":"NCT00948077","phase":"NA","title":"Pharmacokinetic Study for Anti-tuberculosis Drugs","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2009-07","conditions":"Pulmonary Tuberculosis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INH"],"phase":"phase_3","status":"active","brandName":"Isoniazid Oral Product","genericName":"Isoniazid Oral Product","companyName":"Wits Health Consortium (Pty) Ltd","companyId":"wits-health-consortium-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival. Used for Tuberculosis (TB) - active disease treatment, Tuberculosis latent infection prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}